ReviewFrontiers in oncology2026
Research progress on HPV-related vaginal wall lesions after hysterectomy.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hysterectomy is one of the most commonly performed gynecological surgeries worldwide. Vaginal wall lesions after hysterectomy, particularly vaginal intraepithelial neoplasia (VaIN) associated with High-risk human papillomavirus (HR-HPV) infection, have become a focal point in gynecological oncology research. With the widespread implementation of cervical cancer screening programs and the increasing awareness of HPV-related diseases, the detection rate of VaIN has gradually increased. This review systematically analyzes the research progress in various aspects of HPV-related vaginal wall lesions after hysterectomy, including epidemiological characteristics, risk factors, pathogenesis, clinical features, diagnostic strategies, treatment modalities, and follow-up management. Epidemiological studies have shown that although VaIN accounts for less than 1% of all lower genital tract precancerous lesions, its incidence is significantly higher in patients who have undergone hysterectomy for cervical intraepithelial neoplasia (CIN) or cervical cancer. The main risk factors include age, menopausal status, preoperative high-grade CIN, high-risk HPV infection (especially HPV16 and HPV18), immunosuppressive status, surgical approach, positive surgical margins, smoking, multiple sexual partners, and vaginal microecological disorders. The pathogenesis of VaIN after hysterectomy is complex and multifactorial. Persistent HPV infection plays a central role. The E6 and E7 oncoproteins of high-risk HPV promote malignant transformation by degrading p53 and inactivating retinoblastoma protein (pRb), leading to uncontrolled cell proliferation. Surgery-induced anatomical changes, local immune microenvironment alterations, and latent HPV reactivation collectively contribute to VaIN development. Diagnosis requires a standardized approach combining HPV testing, liquid-based cytology (TCT), colposcopy, and targeted biopsy. Colposcopic examination should focus on the vaginal apex, suture line, and lateral fornices where lesions commonly hide. Treatment should be individualized based on lesion grade, extent, location, patient age, fertility requirements, and previous treatments. Options include surgical excision (partial vaginectomy, vaginal apex resection), ablative therapy (CO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.